Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.57 |
| ▸ | USP2 | O75604 | 7/20 | 0.57 |
| ▸ | CYP1A2 | P05177 | 7/20 | 0.57 |
| ▸ | CASP1 | P29466 | 6/20 | 0.57 |
| ▸ | CASP7 | P55210 | 6/20 | 0.57 |
| ▸ | HSD17B10 | Q99714 | 6/20 | 0.57 |
| ▸ | HIF1A | Q16665 | 5/20 | 0.57 |
| ▸ | LMNA | P02545 | 4/20 | 0.57 |
| ▸ | MEN1 | O00255 | 4/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.57 |
| ▸ | TSHR | P16473 | 1/20 | 0.57 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.57 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.57 |
| ▸ | HPGD | P15428 | 2/20 | 0.54 |
| ▸ | BRCA1 | P38398 | 1/20 | 0.54 |
| ▸ | HBB | P68871 | 1/20 | 0.54 |
| ▸ | GSR | P00390 | 2/20 | 0.53 |
| ▸ | GAA | P10253 | 3/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11393995 | 0.94 | ALDH1A1 (0.56) | ALDH1A1USP2CYP1A2CASP1CASP7 | |
| SCHEMBL28950141 | 0.86 | ALDH1A1 (0.60) | ALDH1A1USP2CYP1A2CASP7HSD17B10 | |
| SCHEMBL30139989 | 0.86 | ALDH1A1 (0.60) | ALDH1A1USP2CYP1A2CASP7HSD17B10 | |
| SCHEMBL28950136 | 0.79 | ALDH1A1 (0.77) | ALDH1A1USP2CYP1A2CASP1CASP7 | |
| SCHEMBL30139985 | 0.79 | ALDH1A1 (0.77) | ALDH1A1USP2CYP1A2CASP1CASP7 | |
| SCHEMBL11399920 | 0.79 | PTGS2 (0.51) | ALDH1A1CYP1A2HSD17B10LMNAMEN1 | |
| SCHEMBL8022202 | 0.79 | PTGS2 (0.69) | ALDH1A1CYP1A2LMNAMEN1KMT2A | |
| SCHEMBL979635 | 0.79 | CFTR (0.64) | ALDH1A1USP2CYP1A2CASP1CASP7 | |
| SCHEMBL11395176 | 0.77 | CYP1A2 (0.65) | ALDH1A1USP2CYP1A2CASP1CASP7 | |
| SCHEMBL11399373 | 0.77 | GSR (0.52) | ALDH1A1CYP1A2HSD17B10LMNAMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020086866-A1 | Quinoxalinones as serine protease inhibitors | DUDLEY DANETTE ANDREA (US) | 2002-07-04 | — | — | US | claimed |
| US-6410536-B1 | ANTICOAGULANTS | WARNER-LAMBERT COMPANY | 2002-06-25 | — | — | US | claimed |
| EP-1068190-A1 | QUINOXALINONES AS SERINE PROTEASE INHIBITORS SUCH AS FACTOR XA AND THROMBIN | WARNER-LAMBERT COMPANY LLC (US) | 2001-01-17 | — | — | EP | claimed |
| WO-1999050254-A1 | QUINOXALINONES AS SERINE PROTEASE INHIBITORS SUCH AS FACTOR XA AND THROMBIN | WARNER-LAMBERT COMPANY (US) | 1999-10-07 | — | — | WO | claimed |
| US-6916805-B2 | Quinoxalinones as serine protease inhibitors | WARNER-LAMBERT COMPANY LLC (US) | 2005-07-12 | — | — | US | disclosed |
| US-20020086866-A1 | Quinoxalinones as serine protease inhibitors | DUDLEY DANETTE ANDREA (US) | 2002-07-04 | — | — | US | disclosed |
| US-6410536-B1 | ANTICOAGULANTS | WARNER-LAMBERT COMPANY | 2002-06-25 | — | — | US | disclosed |
| EP-1068190-A1 | QUINOXALINONES AS SERINE PROTEASE INHIBITORS SUCH AS FACTOR XA AND THROMBIN | WARNER-LAMBERT COMPANY LLC (US) | 2001-01-17 | — | — | EP | disclosed |
| WO-1999050254-A1 | QUINOXALINONES AS SERINE PROTEASE INHIBITORS SUCH AS FACTOR XA AND THROMBIN | WARNER-LAMBERT COMPANY (US) | 1999-10-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020086866-A1 | Quinoxalinones as serine protease inhibitors | HABP2, SERPINB1, PRSS1 | ALDH1A1 1960/4885USP2 1301/4885CYP1A2 659/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.